Since high glucose-induced peritoneal pseudohypoxia and elevated HIF-1α are important mechanisms of peritoneal fibrosis and dysfunction, and SGLT2 inhibitors can improve renal fibrosis by ameliorating renal hypoxia and inhibiting HIF-1α in diabetic nephropathy (Bessho et al., 2019; Packer, 2021; Inada et al., 2022), we hypothesized that SGLT2 inhibitors might improve peritoneal function by ameliorating peritoneal hypoxia, decreasing HIF-1α levels, and inhibiting high glucose-induced peritoneal fibrosis. The gene discussed is SLC5A2; the disease is diabetic kidney disease.